Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
Fujita N, Hatakeyama S, Tabata R, Okita K, Kido K, Hamano I, Tanaka T, Noro D, Tokui N, Suzuki Y, Yoneyama T, Hashimoto Y, Sato S, Ohyama C. Fujita N, et al. Among authors: tokui n. Prostate Int. 2024 Mar;12(1):46-51. doi: 10.1016/j.prnil.2023.12.002. Epub 2023 Dec 19. Prostate Int. 2024. PMID: 38523900 Free PMC article.
Impact of bacillus Calmette-Guérin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy.
Horiguchi H, Yoneyama T, Hatakeyama S, Tokui N, Sato T, Fujita N, Yamamoto H, Tobisawa Y, Yoneyama T, Hashimoto Y, Koie T, Yoshikawa K, Narita S, Kawaguchi T, Ohyama C. Horiguchi H, et al. Among authors: tokui n. Med Oncol. 2018 Feb 26;35(4):41. doi: 10.1007/s12032-018-1102-y. Med Oncol. 2018. PMID: 29480348
Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
Tanaka T, Hatakeyama S, Numakura K, Kido K, Noro D, Oikawa M, Hosogoe S, Tokui N, Yamamoto H, Narita S, Ito H, Yoneyama T, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C. Tanaka T, et al. Among authors: tokui n. Int J Urol. 2020 Dec;27(12):1095-1100. doi: 10.1111/iju.14363. Epub 2020 Sep 6. Int J Urol. 2020. PMID: 32893401
Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T, Hatakeyama S, Tanaka T, Kubota Y, Togashi K, Hosogoe S, Fujita N, Kusaka A, Tokui N, Okamoto T, Yamamoto H, Yoneyama T, Yoneyama T, Hashimoto Y, Ohyama C. Hamaya T, et al. Among authors: tokui n. BJU Int. 2021 Oct;128(4):468-476. doi: 10.1111/bju.15346. Epub 2021 Feb 15. BJU Int. 2021. PMID: 33484231 Free PMC article.
The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma.
Okita K, Hatakeyama S, Hagiwara K, Suzuki Y, Tanaka T, Noro D, Tokui N, Fujita N, Konishi S, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Okita K, et al. Among authors: tokui n. Urol Oncol. 2021 Dec;39(12):832.e17-832.e23. doi: 10.1016/j.urolonc.2021.03.011. Epub 2021 Apr 14. Urol Oncol. 2021. PMID: 33865689
Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
Narita T, Hatakeyama S, Numakura K, Kobayashi M, Muto Y, Saito M, Narita S, Tanaka T, Noro D, Tokui N, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C. Narita T, et al. Among authors: tokui n. Int J Urol. 2021 Sep;28(9):899-905. doi: 10.1111/iju.14601. Epub 2021 May 24. Int J Urol. 2021. PMID: 34028105
The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.
Ozaki K, Hatakeyama S, Tanaka T, Noro D, Tokui N, Horiguchi H, Okuyama Y, Fujita N, Okamoto T, Okamoto A, Suzuki Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Ozaki K, et al. Among authors: tokui n. BJUI Compass. 2021 Oct 8;3(2):139-145. doi: 10.1002/bco2.119. eCollection 2022 Mar. BJUI Compass. 2021. PMID: 35474727 Free PMC article.
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
Okuyama Y, Hatakeyama S, Numakura K, Narita T, Tanaka T, Miura Y, Sasaki D, Noro D, Tokui N, Okamoto T, Yamamoto H, Narita S, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C. Okuyama Y, et al. Among authors: tokui n. BJUI Compass. 2021 Oct 8;3(2):154-161. doi: 10.1002/bco2.118. eCollection 2022 Mar. BJUI Compass. 2021. PMID: 35474728 Free PMC article.
83 results